Söndag 17 Maj | 16:19:05 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Spago Nanomedical reaches primary endpoint in Tumorad-01
2026-05-08 10:10:00

Spago Nanomedical's phase I/IIa study Tumorad-01 has met its primary endpoint of identifying the maximum tolerated dose, marking a clinical milestone for the company. In addition to the safety data, new observations of tumour uptake in head and neck cancer patients provide further proof-of-concept for the candidate 177Lu-SN201. These results provide a solid foundation for the upcoming transition into phase II. BioStock reached out to CEO Mats Hansen for a comment.

Read the full interview at biostock.se:

Spago Nanomedical reaches primary endpoint in Tumorad-01

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden